First Treatment for Transthyretin Amyloidosis Cardiomyopathy Approved in Europe
source: pixabay.com

First Treatment for Transthyretin Amyloidosis Cardiomyopathy Approved in Europe

As originally reported in Pfizer, the European Commission has just approved the first treatment option ever available to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM). The medication, VYNDAQEL, taken orally once daily,…

Continue Reading First Treatment for Transthyretin Amyloidosis Cardiomyopathy Approved in Europe